VFF— AI Stock Forecast & Price Targets
Published 6/14/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live VFF price forecast →
Village Farms (VFF) has sold off ~44% YTD to $2.03, sitting near 52-week lows with RSI at 28 (oversold) despite improving fundamentals — TTM EPS growth of 205%, 18.6% profit margins, and a forward P/E of 7.3-8.1. The Kronos AI model is constructively bullish across 1h/4h/1d horizons but bearish on the weekly, and the analyst consensus target of $4.92 (Recom 1.00) implies ~142% upside, suggesting an asymmetric setup for patient accumulators willing to stomach cannabis-segment volatility.
1-4 weeks: Oversold bounce setup. RSI 28, price at forecast-low band, and 1h/4h Kronos targets imply a tactical long toward $2.30-2.50 with stop below $1.85 (recent low). Size small (1-2% portfolio) given the daily forecast still skews to $1.70. Invalidation: weekly close below $1.85.
1-6 months: Constructive on accumulation between $1.70-2.10. Base case targets $2.80-3.20 (Kronos 4h forecast of $3.52, prior resistance). Catalysts: Q2 2026 earnings (likely August), continued US cannabis regulatory progress, evidence Q1 FCF drain was non-recurring. What changes my mind: a second consecutive quarter of negative operating cash flow, gross margin compression below 38%, or breach of $1.50.
1-3 years: Thesis is multi-segment optionality — Canadian cannabis profitability, US CBD scale-up, Netherlands EU export hub, and produce/clean energy as ballast. With book value $2.58 and consensus target $4.92, fair value sits in the $3.50-5.00 range. Structural risk: cannabis remains a commoditized, oversupplied market with chronic pricing pressure; VFF's edge (greenhouse cost structure) could erode if competitors consolidate. Secondary risk: US federal cannabis policy remains the binary swing factor.
Fundamentals are mixed but improving. Q1 2026 revenue of $50.2M was down sequentially from $66.7M in Q3'25 and Q2'25's $59.9M (Sales Y/Y TTM -32.4%, Sales Q/Q -34.8%), reflecting cannabis pricing pressure and possibly divested produce operations. However, profitability has structurally improved: gross margin 41.7%, operating margin 10.0% in Q1'26, with TTM net margin of 18.6% and EPS of $0.36 (P/E 5.6, forward P/E 7.3, PEG 0.23). Balance sheet is solid — $50.5M cash vs. $40.5M debt, current ratio 3.06, debt/equity 0.14, stockholders' equity $294M (book/sh $2.58 vs. price $2.03, so P/B 0.79 — trading below book). The concern: Q1'26 operating cash flow was -$16.8M and FCF -$26.0M, a sharp reversal from positive $23.6M FCF in Q3'25, suggesting working capital drain or seasonal weakness that needs monitoring. ROE 9.6%, ROIC 12.8% are respectable for the sector. Capital allocation appears disciplined (no dividend, modest capex ~$9M/quarter).
Multi-timeframe picture is conflicted. On the 1h chart, price collapsed from ~$2.50 to $2.03 in early June (a ~20% gap-down), and Kronos forecasts a sharp mean-reversion rebound to $2.89 (~42% upside in weeks). The 4h chart shows the same capitulation with forecast targeting $3.52 by Sep, near the early-March highs. The 1d chart is more sobering — forecast at $1.695 (below current $2.03), implying further downside into the $1.50-1.70 zone before stabilization. The 1wk chart shows a long-term downtrend from $11 (2022) to $1 (2023), a 4x rally to $4 in 2025, and now a retest with forecast at $3.63 over 2+ years. RSI at 28 confirms oversold; price is -15.5% below SMA20, -22.6% below SMA50, -34.6% below SMA200 — extended to the downside. Key support: $1.50-1.70 (forecast band low and prior consolidation). Resistance: $2.50, then $2.90, then $3.50. Short float 4.97% is moderate. The divergence between bullish short-term forecasts and bearish daily forecast is a yellow flag — suggests a bounce is plausible but the larger trend remains broken.
News flow is thin but positive: the lone VFF-specific article (Insider Monkey, May 31) flags VFF as a top CBD pick, noting +110% gain over the prior year and analyst expectations of +77% upside, with Q1 2026 results released May 11. There are no negative or material catalysts in the provided feed. The broader market context (crypto, stablecoins, tokenization) is irrelevant to VFF's thesis. Signal: the equity story is being rebuilt around US CBD optionality and stabilized cannabis margins; noise: the recent ~30% quarterly drawdown appears sentiment/sector-driven rather than company-specific given Q1 net income was still positive at $2.9M.
- US Cannabis segment expansion via CBD/hemp products — flagged by Insider Monkey as the core thesis driver
- EPS next 5Y consensus growth of 32.1% supports the PEG of 0.23 — earnings leverage if revenue stabilizes
- Netherlands cannabis operations supplying designated coffee shops — EU regulatory tailwind underappreciated
- Gross margin expansion from 38.7% (Q4'25) to 41.7% (Q1'26) suggests pricing power returning post-shakeout
- Clean Energy segment provides non-correlated cash flow ballast against cannabis cyclicality
- Q1 2026 free cash flow of -$26M reverses prior 3 quarters of positive FCF — must be temporary or thesis breaks
- Revenue declined 34.8% Q/Q and TTM sales are -32.4% Y/Y, indicating ongoing top-line contraction
- Daily Kronos forecast of $1.695 implies ~16% additional downside risk before stabilization
- Cannabis sector remains structurally oversupplied with chronic price compression in Canada
- Stock is -42.8% over 6 months and -29.3% over the quarter — clear distribution/loss of holder confidence
- Low institutional ownership (21.6%) means limited stable shareholder base; high retail beta (1.27)
- US federal cannabis reform timeline is uncertain — a binary catalyst that could whipsaw the equity
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord